Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

HIV Market Snapshot: Gilead's Biktarvy Set To Soar, But ViiV May Win In The End

Executive Summary

Gilead's Biktarvy (B/F/TAF) single tablet is poised to become a huge success, surpassing competitors in the HIV market by far, but the GlaxoSmithKline-backed ViiV Healthcare looks better positioned in the long run.

Advertisement

Related Content

Insurer Incentives For Lower-Cost HIV Drugs Not Seen As Significant Threat For Gilead, ViiV
ViiV/Janssen's Long-Acting Anti-HIV Injections Impress
J&J’s Symtuza Approved, But Commercial Outlook Uncertain
Gilead's Biktarvy Set For EU Approval
Walmsley: GSK Is 'Prepared' And 'Ready' For US Advair Generic Launch
Gilead's CAR-T Therapy Yescarta Slowly Getting Off The Ground
ViiV's Two-Drug HIV Tablet Juluca Is Disruptive, Yet Uptake May Be Slow
Is Gilead Vulnerable to ViiV As It Nears End Of HIV R&D Activity?
Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC100285

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel